Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preconditioned Autologous BMMSCs for Ischemic Heart Disease
NCT02504437Phase 2Unknown
- Start
- Nov 2015
- Primary completion
- Dec 2017
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, randomised, double-blind trial of autologous bone-marrow mesenchymal stem cells in ischemic heart disease (IHD) (3 arms). Primary endpoint: Left Ventricular Ejection Fraction at 1 year. Status: unknown.
02
Drugs
autologous bone-marrow mesenchymal stem cells
03
Conditions
ischemic heart disease (IHD)
Beyond the preview
Go deeper on NCT02504437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02504437.